Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells.

Kim HS, Hong SH, Oh SH, Kim JH, Lee MS, Lee MK

The Journal of endocrinology29 Apr 2013Cited by 22 (Europe PMC)

PMID23503774DOI10.1530/joe-12-0474PepBankPUB-23503774

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In mice, ActA and exendin‑4 co-treatment promoted cell proliferation compared with monotherapy groups.
In plain wordsIn mice, ActA and exendin‑4 co-treatment promoted cell proliferation compared with monotherapy groups.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCell proliferation
Study
mousen: not reported in source
Streptozotocin-induced diabetic nude mice
Comparator
ActA or EX-4 monotherapy groups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Co-treatment of mice with ActA and EX-4 promoted cell proliferation, induced expression of pancreatic β-cell-specific markers, and caused glucose-induced insulin secretion compared with the ActA or EX-4 mono-treatment groups respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated human pancreatic ductal cells with ActA and EX-4 in high-glucose media to induce differentiation into insulin-producing cells and transplanted the cells into streptozotocin-induced diabetic nude mice.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2350377401
02AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In mice, ActA and exendin‑4 co-treatment induced pancreatic beta-cell marker expression compared with monotherapy groups.
In plain wordsIn mice, ActA and exendin‑4 co-treatment increased pancreatic cell markers compared with monotherapy groups.
Peptide
Exenatide (exendin-4)
Outcome
IncreasePancreatic beta-cell marker expression
Study
mousen: not reported in source
Streptozotocin-induced diabetic nude mice
Comparator
ActA or EX-4 monotherapy groups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Co-treatment of mice with ActA and EX-4 promoted cell proliferation, induced expression of pancreatic β-cell-specific markers, and caused glucose-induced insulin secretion compared with the ActA or EX-4 mono-treatment groups respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated human pancreatic ductal cells with ActA and EX-4 in high-glucose media to induce differentiation into insulin-producing cells and transplanted the cells into streptozotocin-induced diabetic nude mice.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2350377402
03AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In mice, ActA and exendin‑4 co-treatment caused glucose-induced insulin secretion compared with monotherapy groups.
In plain wordsIn mice, ActA and exendin‑4 co-treatment increased glucose-induced insulin release compared with monotherapy groups.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseGlucose-induced insulin secretion
Study
mousen: not reported in source
Streptozotocin-induced diabetic nude mice
Comparator
ActA or EX-4 monotherapy groups
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Co-treatment of mice with ActA and EX-4 promoted cell proliferation, induced expression of pancreatic β-cell-specific markers, and caused glucose-induced insulin secretion compared with the ActA or EX-4 mono-treatment groups respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated human pancreatic ductal cells with ActA and EX-4 in high-glucose media to induce differentiation into insulin-producing cells and transplanted the cells into streptozotocin-induced diabetic nude mice.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2350377403
04AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic nude mice, transplantation of ductal cells treated with ActA and exendin‑4 in high glucose normalized blood glucose.
In plain wordsIn mice with diabetes, transplanted ductal cells treated with ActA, exendin‑4 and high glucose normalized blood glucose.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseBlood glucose normalization
Study
mousen: not reported in source
Streptozotocin-induced diabetic nude mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
When pancreatic ductal cells treated with ActA and EX-4 in high-glucose media were transplanted into diabetic nude mice, their blood glucose levels normalized and insulin was detected in the graft.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated human pancreatic ductal cells with ActA and EX-4 in high-glucose media to induce differentiation into insulin-producing cells and transplanted the cells into streptozotocin-induced diabetic nude mice.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2350377404
05AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome
In diabetic nude mice, insulin was detected in grafts of ductal cells treated with ActA and exendin‑4 in high glucose.
In plain wordsIn mice with diabetes, insulin was detected in transplanted ductal cells treated with ActA, exendin‑4 and high glucose.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableGraft insulin detection
Study
mousen: not reported in source
Streptozotocin-induced diabetic nude mice
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
When pancreatic ductal cells treated with ActA and EX-4 in high-glucose media were transplanted into diabetic nude mice, their blood glucose levels normalized and insulin was detected in the graft.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated human pancreatic ductal cells with ActA and EX-4 in high-glucose media to induce differentiation into insulin-producing cells and transplanted the cells into streptozotocin-induced diabetic nude mice.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2350377405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.